|
G |
Fli1 |
Fli-1 proto-oncogene, ETS transcription factor |
multiple interactions |
ISO |
anagrelide inhibits the reaction [THPO protein results in increased expression of FLI1 mRNA] |
CTD |
PMID:20586925 |
|
NCBI chr 8:30,831,422...30,950,468
Ensembl chr 8:30,832,753...30,950,433
|
|
G |
Gata1 |
GATA binding protein 1 |
multiple interactions |
ISO |
anagrelide inhibits the reaction [THPO protein results in increased expression of GATA1 mRNA]; anagrelide inhibits the reaction [THPO protein results in increased expression of GATA1 protein] |
CTD |
PMID:20586925 |
|
NCBI chr X:14,529,706...14,537,530
Ensembl chr X:14,529,702...14,537,530
|
|
G |
Itga2b |
integrin subunit alpha 2b |
multiple interactions |
ISO |
anagrelide inhibits the reaction [THPO protein results in increased expression of ITGA2B mRNA] |
CTD |
PMID:20586925 |
|
NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168
|
|
G |
Mpl |
MPL proto-oncogene, thrombopoietin receptor |
multiple interactions |
ISO |
anagrelide inhibits the reaction [THPO protein results in increased expression of MPL mRNA] |
CTD |
PMID:20586925 |
|
NCBI chr 5:131,973,895...131,987,472
Ensembl chr 5:131,973,895...131,986,797
|
|
G |
Nfe2 |
nuclear factor, erythroid 2 |
multiple interactions |
ISO |
anagrelide inhibits the reaction [THPO protein results in increased expression of NF-E2 mRNA] |
CTD |
PMID:20586925 |
|
NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
increases expression |
ISO |
anagrelide results in increased expression of PDGFB mRNA |
CTD |
PMID:15682418 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
ISO |
anagrelide results in decreased expression of TGFB1 mRNA |
CTD |
PMID:15682418 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thpo |
thrombopoietin |
multiple interactions |
ISO |
anagrelide inhibits the reaction [THPO protein results in increased expression of FLI1 mRNA]; anagrelide inhibits the reaction [THPO protein results in increased expression of GATA1 mRNA]; anagrelide inhibits the reaction [THPO protein results in increased expression of GATA1 protein]; anagrelide inhibits the reaction [THPO protein results in increased expression of ITGA2B mRNA]; anagrelide inhibits the reaction [THPO protein results in increased expression of MPL mRNA]; anagrelide inhibits the reaction [THPO protein results in increased expression of NF-E2 mRNA]; anagrelide inhibits the reaction [THPO protein results in increased expression of ZFPM1 mRNA] |
CTD |
PMID:20586925 |
|
Ensembl chr11:80,182,820...80,188,167
|
|
G |
Zfpm1 |
zinc finger protein, multitype 1 |
multiple interactions |
ISO |
anagrelide inhibits the reaction [THPO protein results in increased expression of ZFPM1 mRNA] |
CTD |
PMID:20586925 |
|
NCBI chr19:50,334,352...50,391,029
Ensembl chr19:50,334,682...50,390,591
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
copanlisib results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:31445927 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Fas |
Fas cell surface death receptor |
affects response to substance |
ISO |
copanlisib affects the susceptibility to FAS protein |
CTD |
PMID:31445927 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Tnf |
tumor necrosis factor |
increases response to substance |
ISO |
copanlisib results in increased susceptibility to TNF protein |
CTD |
PMID:31445927 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|